What this pack is
VIAGRA is the brand name in this record; sildenafil is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
VIAGRAGeneric namesildenafil
Mainland China pack-name cue万艾可®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
The cited U.S. label describes sildenafil as a selective inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase type 5 (PDE5). It explains a drug-action pathway; it does not determine anyone's erection, chest pain, blood pressure, cardiovascular risk, suitability, tablet count or combination plan with another product.
Read source: United States ↗reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 万艾可®
- International brand name
- VIAGRA
- Generic name
- sildenafil
- Dosage-form class
- Oral film-coated tablets: 25 mg, 50 mg and 100 mg (each listed in the cited U.S. public label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
Mainland China trade-name search cue:万艾可®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v32 (effective 2017-12-15)
VIAGRA sildenafil 25 mg, 30-tablet bottle
- Product code
- NDC 0069-4200-30
- Form and route
- film-coated oral tablet · oral
- Sildenafil (per tablet)
- 25 mgLabelled amount per tablet; not an individual dose
- Package
- 30 tablets
- Labelled appearance
- blue · rounded diamond · imprint VGR25 / PFIZERUnscored in this labelled presentation
United States label · DailyMed SPL v32 (effective 2017-12-15)
VIAGRA sildenafil 50 mg, 30-tablet bottle
- Product code
- NDC 0069-4210-30
- Form and route
- film-coated oral tablet · oral
- Sildenafil (per tablet)
- 50 mgLabelled amount per tablet; not an individual dose
- Package
- 30 tablets
- Labelled appearance
- blue · rounded diamond · imprint VGR50 / PFIZERUnscored in this labelled presentation
United States label · DailyMed SPL v32 (effective 2017-12-15)
VIAGRA sildenafil 100 mg, 30-tablet bottle
- Product code
- NDC 0069-4220-30
- Form and route
- film-coated oral tablet · oral
- Sildenafil (per tablet)
- 100 mgLabelled amount per tablet; not an individual dose
- Package
- 30 tablets
- Labelled appearance
- blue · rounded diamond · imprint VGR100 / PFIZERUnscored in this labelled presentation
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
VIAGRA label reading: 25, 50 and 100 mg identify different tablets; they are not a formula for self-adjusting tablet count
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the cited dated U.S. DailyMed label to check VIAGRA, sildenafil, 25/50/100 mg per tablet, blue rounded-diamond appearance, imprints, NDCs and 30-tablet bottles. It does not provide an individual's tablet count, start, stop, combination, switch or conversion plan with another sildenafil product.
- Check VIAGRA, sildenafil, 25, 50 or 100 mg per tablet, oral-tablet form, NDC, bottle count and target market as one set. Milligrams are the labelled amount in an exact tablet, not a web rule for personal tablet count, escalation, make-up use or replacing one pack with another.
- The cited label describes all three strengths as blue rounded-diamond film-coated tablets and distinguishes them with VGR25, VGR50 or VGR100 plus PFIZER. Colour, shape or a single number are identity clues only; a photograph, appearance or shared ingredient cannot authenticate a product, establish current packaging or establish interchangeability.
- The label lists organic nitrates or nitric-oxide donors in any form as a contraindication and flags other products that can affect blood pressure or drug exposure for professional review. With cardiovascular, urinary, OTC, supplement or herbal products, take the complete medicine list to a pharmacist or prescriber for item-by-item review; do not self-stop, separate, stack or borrow medicines from a webpage.
- With chest pain, fainting, sudden vision or hearing changes, or another acute serious concern, prioritise local emergency care; do not wait for a website search or self-counteract, adjust or make up use with another pack.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): U.S. VIAGRA sildenafil public label (Pfizer; SPL v32, effective 15 Dec 2017) ↗reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about VIAGRA (sildenafil). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
VIAGRA is the brand in this record and sildenafil is the active-ingredient name. Check both with the dosage form (Oral film-coated tablets: 25 mg, 50 mg and 100 mg (each listed in the cited U.S. public label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How sildenafil works: it selectively inhibits PDE5, but mechanism does not decide individual suitability
- Read PDE5 as one biological pathway through which this medicine acts. Mechanism wording cannot infer the cause of a person's symptoms or replace professional review of cardiovascular status, blood pressure, prior reactions, the complete medicine list and exact product label.
- Products that share sildenafil, mention PDE5 or look similarly coloured do not automatically become interchangeable, combinable or milligram-convertible. Dosage form, market, strength, other ingredients and the current label all need item-by-item review.
- For concerns about interactions, prior effects, cardiovascular issues or products such as nitrates, the most useful next step is to bring the exact pack and complete medicine list to a pharmacist or clinician; a mechanism explanation cannot replace that review.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): U.S. VIAGRA sildenafil public label (Pfizer; SPL v32, effective 15 Dec 2017) ↗reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
VIAGRAsildenafil
This page links to public primary-source material for VIAGRA. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the cited label
The cited U.S. DailyMed public label for VIAGRA lists Initial U.S. Approval: 1998. This year only locates the history of this U.S. label; it does not establish approval, supply, sale eligibility, originator/generic relationship, interchangeability or individual suitability in Mainland China, the EU, Japan or another market.
DailyMed (NLM): U.S. VIAGRA sildenafil public label (Pfizer; SPL v32, effective 15 Dec 2017) ↗Effective date of the cited DailyMed SPL v32
The cited VIAGRA label is SPL v32 with an effective time of 15 Dec 2017. This page separately displays the label identities for the 30-tablet bottles: 25 mg/NDC 0069-4200-30, 50 mg/NDC 0069-4210-30 and 100 mg/NDC 0069-4220-30. This dated record does not establish current marketing, stock, purchase, individual tablet count, co-use, stopping, switching or another-market status.
DailyMed (NLM): U.S. VIAGRA sildenafil public label (Pfizer; SPL v32, effective 15 Dec 2017) ↗
MARKET SCOPE
Market-record boundary
United States
Dated public label and three exact 30-tablet bottle identities linkedThis page records the label panels for VIAGRA sildenafil 25 mg/NDC 0069-4200-30, 50 mg/NDC 0069-4210-30 and 100 mg/NDC 0069-4220-30 30-tablet bottles. They are only for reading brand, generic name, labelled amount per tablet, NDC, package and source; they do not authenticate a product or establish current marketing, stock, purchase, individual tablet count, initiation, stopping, co-use, switching or interchangeability.
Mainland China, EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the historical U.S. label, SPL, NDC, English brand, package image or label holder; every market requires separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
Mainland China trade-name search cue: 万艾可®
This cue helps read packaging and search official records. It does not establish current approval, holder, strength, originator relationship, supply or sale eligibility. Open historical reference ↗
RECORD FAQ
Record questions
Can 25, 50 or 100 mg, or a 30-tablet bottle, tell me how many to take, whether to adjust, or whether I can change to another sildenafil product?
No. These fields only identify exact products and packs in the cited U.S. label. A shared ingredient, nearby milligram number, appearance or package photo does not establish self-initiation, increase, make-up use, stopping, co-use, alternation or substitution; have a pharmacist or prescriber review the actual pack, current prescription and complete medicine list.
Why does the page mention nitrates, chest pain and acute concerns without telling me whether to stop?
These are reading entry points for contraindications and warnings in the cited U.S. label, not an individual risk assessment or treatment decision. With chest pain, fainting, sudden vision or hearing changes, or another acute serious concern, prioritise local emergency medical support; any product change needs review by a professional who knows the actual prescription, history and complete medicine list.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.